Other News

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it will attend BioTrinity 2018.  BioTrinity is one of Europe’s leading biopartnering and investment conferences, to be held on 23-25 April at the Novotel London West. Click here to read more....

Read More

Oxford, UK, 5th May 2017: Physiomics is pleased to announce that it will attend BioTrinity 2017. BioTrinity is one of Europe’s leading Biopartnering and Investment Conferences, to be held on 8-10 May at the Novotel London West. In addition to participating in a number of partnering meetings, Physiomics will present an update on its technology at the conference on Tuesday 9th May. Dr Jim Millen, CEO,...

Read More

Physiomics to give an oral presentation on developments of the Virtual Tumour platform in drug resistance at the Seventh American Conference on Pharmacometrics (“ACoP7”) Physiomics plc (AIM: PYC), the Oxford, UK based systems biology Company, is pleased to announce that it is participating in the ACoP7 Meeting 2017, taking place at the Hyatt Regency Bellevue, Washington on 24-26 October 2016. Dr David Orrell, Principal Consultant, will...

Read More

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce the appointment of Hybridan LLP as joint broker with immediate effect. Please click here for full information.  ...

Read More

Dr Christophe Chassagnole, COO and Dr Eric Fernandez, Project Leader will be both present at PAGE 2016. Dr Fernandez will present on modelling radiation therapy in the poster session I on the 8th of June at 10:20 and Dr Christophe Chassagnole will present on the newest development of the Virtual Tumour in drug resistance in the poster session II on the 8th of June at 15:10. Please click here...

Read More

If you missed any of our past webinars, you can now view them online! Under the Publications menu, you can now find a new Webinars section. If you have further questions about our services or products, please contact us using this form or directly at info@physiomics-plc.com....

Read More

Physiomics plc is pleased to announce that it has appointed Professor Mark Middleton to its Scientific Advisory Board. Professor Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford. He is an eminent clinician with highly relevant clinical experience. Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research...

Read More

Dr Hugues Dolgos, Global Head, Quantitative Pharmacology & Drug Disposition, Merck Serono, is presenting at the Quantitative Systems Pharmacology meeting today in Basel, Switzerland. His presentation, entitled “Transforming Modeling & Simulation at Merck-Serono to Implement the Translational Medicine Strategy”, will include a section on Physiomics technology. ...

Read More
})(jQuery)